Open AccessAH23848: a thromboxane receptor-blocking drug that can clarify the pathophysiologic role of thromboxane A2.
Author(s) -
R T Brittain,
L Boutal,
M C Carter,
Robert A. Coleman,
E. W. COLLINGTON,
H P Geisow,
Penelope J. Hallett,
E J Hornby,
P.P.A. Humphrey,
David Jack
Publication year - 1985
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/01.cir.72.6.1208
Subject(s) - medicine , thromboxane a2 , thromboxane , drug , thromboxane receptor , pharmacology , receptor , blocking (statistics) , pathophysiology , platelet , statistics , mathematics
Despite numerous suggestions in the literature that thromboxane A2 is involved in a variety of occlusive vascular diseases, no definitive evidence is available. Arguments have been presented to support the view that such evidence can only come from clinical studies with a highly specific thromboxane receptor-blocking drug. We have now identified such a drug, AH23848, in our laboratories. Preliminary experiments with AH23848, ([1 alpha (Z), 2 beta,5 alpha]-(+/-)-7-[5-[[(1,1'-biphenyl)-4-yl]methoxy]-2-(4-morpholin yl)-3-oxocyclopentyl]-4-heptenoic acid), show that it is a potent, specific thromboxane receptor-blocking drug that is orally active and has a long duration of action. It should be a valuable tool in elucidating any physiologic or pathologic role of thromboxane A2.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom